Over-Myr has ended June 30th. Feel free to browse the website for any more information or have a look at the final publishable summary summing up the work carried out during the lifetime of the project.
OVER-Myr has ended on June 30th, the website will stay alive for another year.
Results of the excellent work carried out in Over-Myr can be found in the
Final Publishable Summary
Welcome to the OVER-MyR project web interface - Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance -
Multiple Myeloma (MM) is a universally fatal malignant plasma cell disease which remains incurable. Signs and symptoms of myeloma are associated with accumulation of malignant plasma cells in the bone marrow and the production of a monoclonal protein. It is associated with considerable morbidity and can substantially affect the quality of life.
Patients invariably relapse after each subsequent treatment regimen, become resistant to treatment, and succumb to their disease. Our network sets out to address this urgent issue, and proposes a strategy to overcome multiple myeloma resistance (OVER-MyR) by implementing a tight collaboration of network partners gathering outstanding clinical, biological and basic research expertise.
OVER-MyR is funded by the European Commission within its FP7 specific programme Cooperation; contract no 278706; official starting date is 1st January 2012.